Complex metabolic pathway illustrating the glucocorticoid-Angptl4-ceramide axis leading to insulin resistance.

Unlocking the Mystery: How Glucocorticoids, Angptl4, and Ceramides Impact Insulin Resistance

Author's portrait.
Reese Marlowe in Health & Wellness July 2025 • 4 min read.

"A groundbreaking study reveals the intricate connection between glucocorticoid exposure, Angptl4, and ceramide production in driving insulin resistance, offering potential new therapeutic targets."


Insulin resistance is a growing health concern, acting as a major precursor to type 2 diabetes and cardiovascular diseases. While the role of glucocorticoids—hormones essential for regulating various bodily functions—in inducing insulin resistance has long been recognized, the precise mechanisms have remained elusive.

Emerging research has shed light on a critical pathway involving Angptl4 (angiopoietin-like 4), a protein regulated by glucocorticoids, and ceramides, a class of lipids. This axis appears to play a pivotal role in how glucocorticoids trigger insulin resistance, offering new targets for therapeutic intervention.

This article explores the groundbreaking study that unveils the intricate relationship between glucocorticoids, Angptl4, and ceramides, delving into the molecular mechanisms that drive insulin resistance. By understanding this complex interplay, we can pave the way for innovative strategies to combat metabolic disorders and improve overall health.

The Glucocorticoid-Angptl4-Ceramide Connection: A Deep Dive

Complex metabolic pathway illustrating the glucocorticoid-Angptl4-ceramide axis leading to insulin resistance.

The study, conducted by researchers at the University of California, Berkeley, focused on the effects of chronic glucocorticoid exposure on insulin resistance. They discovered that Angptl4, a glucocorticoid target gene, plays a crucial role in mediating glucocorticoid-induced lipolysis (the breakdown of fats) in white adipose tissue (WAT).

Through meticulous metabolomic profiling, the researchers found that glucocorticoid treatment led to increased hepatic ceramide concentrations. This increase was dependent on Angptl4, which stimulated the activity of enzymes involved in ceramide synthesis. Furthermore, Angptl4 was essential for glucocorticoids to activate downstream effectors of ceramide, namely protein phosphatase 2A (PP2A) and protein kinase Cζ (PKCζ).

  • Angptl4: A key protein that mediates glucocorticoid-induced lipolysis in white adipose tissue.
  • Ceramides: A class of lipids whose hepatic concentrations increase with glucocorticoid treatment, impacting insulin sensitivity.
  • PP2A and PKCζ: Downstream effectors of ceramide that play a role in insulin resistance.
To further validate their findings, the researchers conducted experiments on mice. They demonstrated that inhibiting PP2A or PKCζ, or blocking ceramide synthesis, prevented glucocorticoid-induced glucose intolerance in wild-type mice. Importantly, these interventions did not further improve glucose tolerance in Angptl4-deficient mice, suggesting that PP2A, PKCζ, and ceramide synthesis are major downstream effectors of Angptl4.

Implications and Future Directions

This study unveils the critical role of Angptl4 in glucocorticoid-augmented hepatic ceramide production, which ultimately induces whole-body insulin resistance. These findings offer valuable insights into the pathogenesis of metabolic disorders and identify potential targets for therapeutic interventions. Further research is needed to fully elucidate the complex interplay between glucocorticoids, Angptl4, ceramides, and other signaling pathways involved in insulin resistance.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What is the main connection between Glucocorticoids, Angptl4, and Ceramides?

The study highlights a crucial pathway: Glucocorticoid exposure leads to increased Angptl4 production, which in turn stimulates hepatic ceramide synthesis. This cascade ultimately results in whole-body insulin resistance. The relationship between these three, Glucocorticoids, Angptl4, and Ceramides, is not isolated, and the mechanisms behind it are interconnected.

2

How does Angptl4 contribute to insulin resistance in this context?

Angptl4, a protein regulated by Glucocorticoids, plays a central role in mediating glucocorticoid-induced lipolysis in white adipose tissue (WAT). The study showed that Angptl4 is essential for glucocorticoids to activate downstream effectors of Ceramide, namely PP2A and PKCζ, which contribute to the development of insulin resistance.

3

What are the implications of the study's findings for potential treatments?

The study identifies Angptl4, Ceramides, PP2A, and PKCζ as potential therapeutic targets. Since inhibiting PP2A or PKCζ, or blocking Ceramide synthesis, prevented glucocorticoid-induced glucose intolerance in mice, these targets offer avenues for interventions to combat insulin resistance and metabolic disorders. This gives a better understanding of the pathogenesis of metabolic disorders.

4

What role do Ceramides play in the development of insulin resistance according to this research?

The research indicates that Glucocorticoid treatment leads to increased hepatic Ceramide concentrations. This increase, dependent on Angptl4, stimulates the activity of enzymes involved in Ceramide synthesis. Higher levels of Ceramides activate downstream effectors like PP2A and PKCζ, ultimately contributing to insulin resistance, and causing glucose intolerance.

5

How was the research validated, and what were the key findings from the experiments on mice?

The researchers validated their findings by conducting experiments on mice. They demonstrated that inhibiting PP2A or PKCζ, or blocking Ceramide synthesis, prevented Glucocorticoid-induced glucose intolerance in wild-type mice. Importantly, these interventions did not further improve glucose tolerance in Angptl4-deficient mice. This suggests that PP2A, PKCζ, and Ceramide synthesis are major downstream effectors of Angptl4.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.